Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022

Amati, Rebecca; Frei, Anja; Kaufmann, Marco; Sabatini, Serena; Pellaton, Céline; Fehr, Jan; Albanese, Emiliano; Puhan, Milo A.

doi:10.2807/1560-7917.es.2022.27.31.2200561

Cited by 16 publications

(25 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are a variety of neutralization assays that have been described to be able to measure functional antibody neutralization against wild-type as well as variant SARS-CoV-2 that involve binding proxy assays ( 24 – 27 ), pseudovirus, or VLP neutralization ( 7 , 25 , 26 ) as well as SARS-CoV-2 culture-based neutralization ( 26 , 28 ). Not all methods compare wild-type or variant SARS-CoV-2 neutralization.…”

Section: Discussionmentioning

confidence: 99%

Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The current study includes results from phases five and six, for which assessments were conducted between 1 March and 1 April 2022 and 30 May and 11 July, respectively. 12…”

Section: Methodsmentioning

confidence: 99%

“…The current study includes results from phases five and six, for which assessments were conducted between 1 March and 1 April 2022 and 30 May and 11 July, respectively. 12 In phase five, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in phase six. For cross-sectional analyses in phase six, we supplemented the southern and eastern Switzerland sample with a random sample from the general population in western Switzerland (canton of Vaud).…”

Section: Study Design Sampling and Participantsmentioning

confidence: 99%

Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study

Frei

Kaufmann

Amati

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Background Seroprevalence and the proportion of people with neutralizing activity against SARS-CoV-2 variants was high in early 2022. Since it is unclear how immunity in the general population evolves, the aim of this study was to assess the development of functional and hybrid immunity in the general population during a period of high incidence of infections with Omicron variants. Methods This prospective population based multi-region cohort study is part of the Corona Immunitas research programme in Switzerland. In March 2022, we randomly selected individuals from the general population in southern (canton of Ticino) and north-eastern (canton of Zurich) Switzerland, who were assessed again in June/July 2022. We supplemented the June/July 2022 sample with a random sample from western Switzerland (canton of Vaud). We assessed SARS-CoV-2 specific IgG antibodies against spike and nucleocapsid proteins and the presence of SARS-CoV-2 neutralising antibodies against three variants (wildtype, Delta, Omicron). Findings In June/July 2022, seroprevalence was >98% in 2553 individuals from the general Swiss population. The proportion of individuals with neutralising antibodies against wildtype, Delta, and Omicron was 94.2%, 90.8%, and 84.9%, and at least 51% of the participants developed hybrid immunity. Individuals with hybrid immunity had, compared to those with only vaccine- or infection-induced immunity, highest levels of both, anti-spike IgG antibodies titres (4518 vs. 4304 vs. 269 WHO U/ml) and neutralisation capacity against wildtype (99.8% vs. 98% vs. 47.5%), Delta (99% vs. 92.2% vs. 38.7%), and Omicron (96.4% vs. 79.5% vs. 47.5%). Interpretation This first study on functional and hybrid immunity in the general population after Omicron waves showed that SARS-CoV-2 has become endemic. The high levels of antibodies and neutralization in the general populations support the emerging recommendations of some countries where booster vaccinations are still strongly recommended for vulnerable persons but less strongly recommended for individuals in the general population.

show abstract

“…They were followed-up at two and four months after baseline to elicit data on PCC-related symptoms, current health status, new infections, and vaccinations. 5,21,23 For this study, we included all participants who, either at baseline or during follow-up, reported having last been infected by SARS-CoV-2 during the timeframes of predominance of the Delta and Omicron variants (see definition below), and who completed the baseline or either of the follow-up assessments approximately six months after the most recent reported infection (five to seven months allowed; Supplementary Figure S1).…”

Section: Methodsmentioning

confidence: 99%

“…21,22 For this study, we leveraged data from the fifth phase of Corona Immunitas and associated follow-up from the cantons of Zurich (largest canton in German-speaking north-eastern Switzerland with around 18% of the Swiss population), and Ticino (Italian-speaking part with about 4% of Swiss population), Switzerland, including 1844 participants, for which baseline assessments took place between Mar 1-31, 2022. 23 The study was registered (https://doi.org/10.1186/ISRCTN18181860) and approved by the ethics committees of the cantons of Zurich (BASEC 2020-01247) and Ticino (BASEC 2020-01514). All participants provided informed consent prior to participation.…”

Section: Study Design and Participantsmentioning

confidence: 99%

Post COVID-19 condition after Wildtype, Delta, and Omicron variant SARS-CoV-2 infection and vaccination: pooled analysis of two population-based cohorts

Menges

Kaufmann

Amati

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Post COVID-19 condition (PCC) is an important complication of SARS-CoV-2 infection, affecting millions worldwide. Further evidence is needed on the risk of PCC after vaccination and infection with newer variants. This study aimed to evaluate the prevalence and severity of PCC across different variants and vaccination histories. Methods: We used pooled data from 1350 SARS-CoV-2-infected individuals from two representative population-based cohorts in Switzerland, diagnosed between Aug 5, 2020, and Feb 25, 2022. We descriptively analysed the prevalence and severity of PCC, defined as the presence and frequency of PCC-related symptoms six months after infection, among vaccinated and non-vaccinated individuals infected with Wildtype, Delta, and Omicron SARS-CoV-2. We used multivariable logistic regression models to assess the association and estimate the risk reduction of PCC after infection with newer variants and prior vaccination. We further assessed associations with the severity of PCC using multinomial logistic regression. To identify groups of individuals with similar symptom patterns and evaluate differences in the presentation of PCC across variants, we performed exploratory hierarchical cluster analyses. Findings: We found strong evidence that vaccinated individuals infected with Omicron had a reduced risk of developing PCC compared to non-vaccinated Wildtype-infected individuals (odds ratio 0.42, 95% confidence interval 0.24-0.68). The risk among non-vaccinated individuals was similar after infection with Delta or Omicron compared to Wildtype SARS-CoV-2. We found no differences in PCC prevalence with respect to the number of received vaccine doses or timing of last vaccination. The prevalence of PCC-related symptoms among vaccinated, Omicron-infected individuals was lower across severity levels. In cluster analyses, we identified four clusters of diverse systemic, neurocognitive, cardiorespiratory, and musculoskeletal symptoms, with similar patterns across variants. Interpretation: The risk of PCC appears to be lowered with infection by the Omicron variant and after prior vaccination. This evidence is crucial to guide future public health measures and vaccination strategies. Study registrations: ISRCTN14990068, ISRCTN18181860

show abstract

Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022

Cited by 16 publications

References 18 publications

Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses

Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses

Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study

Post COVID-19 condition after Wildtype, Delta, and Omicron variant SARS-CoV-2 infection and vaccination: pooled analysis of two population-based cohorts

Contact Info

Product

Resources

About